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Objectives:	  To	  illustrate	  that	  the	  protease	  inhibitor	  (PI)	  ritonavir,	  widely	  used	  as	  part	  of	  the	  treatment	  
for	  HIV,	  might	  cause	  drug–drug	  interactions	  with	  inhaled	  corticosteroids.	  	  
	  
Material	  and	  methods:	  A	  case	  report	  is	  presented.	  
	  
Results:	   An	   HIV-­‐positive	   patient	   presented	   with	   gradually	   changing	   body	   composition	   that	   was	  
ascribed	   to	   lipodystrophy.	   Finally,	   iatrogenic	   Cushing’s	   syndrome	   with	   secondary	   adrenal	  
insufficiency	  was	  diagnosed	  due	  to	  a	  drug–drug	  interaction	  of	  ritonavir	  and	  fluticasone.	  	  
	  
Conclusion:	   Lipodystrophy	   might	   mimic	   Cushing’s	   syndrome.	   The	   combination	   of	   ritonavir	   and	  
inhaled	  fluticasone	  may	   lead	  to	  systemic	  steroid	  excess	  causing	  Cushing’s	  syndrome	  and	  secondary	  
adrenal	  insufficiency.	  
	  





Ritonavir,	   a	   protease	   inhibitor	   (PI),	   is	   commonly	   used	   in	   the	   treatment	   of	   HIV-­‐positive	   patients	   to	  
boost	   levels	   of	   other	   PIs	   as	   it	   is	   a	   potent	   inhibitor	   of	   CYP3A4	   activity1.	   Because	   of	   these	  
pharmacological	  characteristics,	  the	  metabolism	  of	  other	  commonly	  used	  drugs	  may	  be	  affected.	  
Intranasal	  and	  inhaled	  corticosteroids	  (ICSs)	  are	  widely	  used	  for	  suppression	  of	  airway	  inflammation	  
in	  conditions	  such	  as	  asthma	  and	  chronic	  obstructive	  lung	  disease	  (COPD).	  Fluticasone	  is	  a	  substrate	  
of	  hepatic	  CYP3A4	  and	  is	  rarely	  reported	  to	  interact	  with	  ritonavir,	  resulting	  in	  steroid	  accumulation,	  
leading	  to	  Cushing’s	  syndrome	  and	  adrenal	  suppression2.	  Detection	  of	  iatrogenic	  Cushing’s	  syndrome	  
is	   particularly	  challenging	   in	  HIV-­‐positive	  patients,	   because	   the	  presence	  of	   lipodystrophy	  as	  a	   side	  
effect	  of	  combination	  antiretroviral	  therapy	  (cART)	  may	  mask	  the	  diagnosis3.	  This	  case	  highlights	  the	  
strong	   drug	   interaction	   between	   inhaled	   fluticasone	   and	   low-­‐dose	   ritonavir,	   leading	   to	   iatrogenic	  
Cushing’s	  syndrome	  and	  secondary	  adrenal	  suppression.	  The	  purpose	  of	  this	  article	  is	  to	  underscore	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A	  55-­‐year-­‐old	  man	  presented	  in	  2013	  for	  a	  routine	  check	  of	  his	  HIV-­‐1	  infection	  that	  had	  been	  treated	  
with	   cART	   since	   2000.	   His	  medical	   history	  
also	   revealed	   COPD,	   hypertension	   and	  
nephrolithiasis.	   Over	   the	   past	   years,	   his	  
cART	   had	   been	   changed	   several	   times	  
because	  of	  presumptive	   lipodystrophy	  and	  
other	   side	   effects.	   His	   current	   medication	  
was	   tenofovir/emtricitabine,	   atazanavir,	  
ritonavir	  (100	  mg	  o.d.)	  and	  amlodipine.	  	  
He	   complained	   of	   progressive	   fatigue,	   an	  
ongoing	   predominant	   rise	   in	   his	   waist	  
circumference	  and	  general	  bone	  pains.	  On	  
examination,	  we	  saw	  a	  healthy	  man	  with	  a	  
blood	   pressure	   of	   142/90	   mmHg.	   He	   had	  
pronounced	   central	   adiposity	   and	   the	  
muscles	   of	   the	   lower	   extremities	   were	  
obvious	  atrophic	  (Fig.	  1).	  	  
	  
Figure	   1:	   Pronounced	   central	   adiposity	   and	   atrophic	  muscles	   of	   the	  
lower	  extremities	  in	  our	  patient	  with	  iatrogenic	  Cushing’s	  syndrome	  	  
	  
We	  did	  not	  notice	  a	  moon	  face	  or	  buffalo	  hump;	  his	  appearance	  had	  not	  changed	  in	  the	  previous	  ten	  
years.	  	  
However,	   based	   on	   his	  
complaints	   and	   body	  
composition,	   we	   considered	  
a	   diagnosis	   of	   Cushing’s	  
syndrome.	   Complementary	  
blood	  and	  urinary	  tests	  were	  





The	   morning	   serum	   cortisol	   levels	   were	   repeatedly	   extremely	   low	   while	   the	   adrenocorticotropic	  
hormone	   (ACTH)	   level	  was	   suppressed.	   	  A	   short	   synthetic	  ACTH	  stimulation	   test	   showed	  a	  blunted	  
response.	  	  
Baseline	  cortisol	  level	  was	  31	  nmol/l	  at	  start	  with	  cortisol	  levels	  of	  66	  nmol/l	  and	  83	  nmol/l	  after	  30	  
and	  60	  min.	  In	  a	  physiological	  situation,	  we	  would	  aspect	  a	  rise	  of	  the	  cortisol	  level	  at	  least	  above	  500	  
nmol/l.	   A	   repeatedly	   low	   excretion	   of	   cortisol	   was	   shown	   by	   24-­‐h	   urinary	   examination.	   A	   bone	  
density	   scan	   revealed	   skeletal	   osteopenia.	   The	   diagnosis	   of	   exogenous	   Cushing’s	   syndrome	   with	  
osteopenia	  and	  secondary	  adrenal	  suppression	  was	  made.	  On	   inquiry,	  the	  patient	  reported	  that	  he	  
had	  been	  using	   intranasal	  and	   inhaled	   fluticasone	  for	  over	   ten	  years.	   It	  had	  been	  prescribed	  by	  his	  
general	   practitioner.	   The	   strong	   interaction	   between	   the	   fluticasone	   and	   ritonavir	   resulted	   in	   this	  
clinical	  and	  biochemical	  picture.	  The	  fluticasone	  was	  stopped	  and	  the	  atazanavir	  and	  ritonavir	  were	  
replaced	  by	  raltegravir.	  To	  prevent	  adrenal	  crisis,	  the	  patient	  was	  put	  on	  steroid	  replacement	  therapy	  
(hydrocortisone	  10	  mg	  o.d.	   and	  5	  mg	  b.i.d.).	   Six	  months	   later,	   his	   general	   condition	  had	   improved	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with	   normalization	   of	   body	   composition;	   retrospectively,	   we	   concluded	   that	   he	   indeed	   had	   had	   a	  




This	   case	   highlights	   the	   strong	   drug	   interaction	   between	   fluticasone	   and	   ritonavir	   leading	   to	  
iatrogenic	   Cushing’s	   syndrome	   with	   osteopenia	   and	   secondary	   adrenal	   suppression.	   Only	   after	  
inquiry	   we	   found	   out	   that	   the	   patient	   was	   using	   inhaled	   and	   intranasal	   fluticasone.	   Therefore,	   a	  
thorough	  medication	  history	  is	  essential	  in	  patients	  with	  symptoms	  and	  clinical	  features	  suggestive	  of	  
Cushing’s	   syndrome.	   Because	   fluticasone	   is	   widely	   prescribed	   for	   common	   pulmonary	   conditions,	  
there	   is	   a	   potential	   increased	   risk	   of	   developing	   steroid	   accumulation	   in	   HIV-­‐positive	   patients	   on	  
ritonavir-­‐based	  cART.	  	  
The	   frequent	   clinical	   phenotype	   of	   lipodystrophy	   due	   to	   antiretrovirals	  may	  mask	   the	   diagnosis	   of	  
Cushing’s	   syndrome.	  Central	   adiposity	   and	  osteopenia	   are	   features	  overlapping	  with	   lipodystrophy	  
and	  Cushing’s	   syndrome,	  but	   the	  presence	  of	  peripheral	  atrophy	  may	  be	  a	  clue	   to	   the	  presence	  of	  
Cushing’s	  syndrome	  [3].	  
A	   recent	   review	   of	   the	   literature	   did	   not	   report	   cases	   of	   iatrogenic	   Cushing’s	   syndrome	   in	   HIV	  
patients	   using	   ICSs	   other	   than	   fluticasone	   [4].	   The	   pharmacokinetics	   of	   fluticasone	   increases	   the	  
likelihood	   of	   systemic	   steroid	   accumulation	   in	   HIV	   patients	   using	   a	   ritonavir-­‐based	   ART	   regimen.	  
Fluticasone	   is	   the	  most	   lipophilic	   ICS	   and	   has	   the	   longest	   glucocorticoid	   receptor-­‐binding	   half-­‐life.	  
Other	   ICSs,	   like	  beclomethasone	   and	  budesonide,	  may	  only	   lead	   to	   iatrogenic	   adrenal	   suppression	  
and	   Cushing’s	   syndrome	   when	   ritonavir	   is	   combined	   with	   other	   potent	   CYP3A4	   inhibitors	   like	  
clarithromycin	  or	  itraconazole	  [5].	  	  
Iatrogenic	   Cushing’s	   syndrome	   due	   to	   exogenic	   steroid	   excess	   is	   a	   clinical	   diagnosis.	   Biochemical	  
support	  comes	  from	  the	  presence	  of	  secondary	  adrenal	  insufficiency	  as	  illustrated	  by	  a	  low	  morning	  
plasma	  cortisol	  and	  ACTH	  level.	  In	  our	  case,	  a	  synthetic	  ACTH	  stimulation	  test	  with	  an	  absent	  rise	  in	  
cortisol	   finally	   confirmed	   the	   diagnosis.	   The	  mainstay	   of	   the	   treatment	   is	   to	   replace	   ritonavir	   and	  
change	   cART	   and/or	   substitution	   of	   the	   fluticasone	   by	   another	   local	   steroid.	   Tapering	   of	   inhaled	  
steroids	  must	  strongly	  be	  considered	  to	  avoid	  steroid	  withdrawal	  symptoms.	  	  
	  
Conclusion	  
Fluticasone	   inhalation	   therapy	   may	   cause	   iatrogenic	   Cushing’s	   syndrome	   with	   secondary	   adrenal	  
insufficiency	  when	  combined	  with	  the	  strong	  CYP3A4	  inhibitor	  ritonavir	  as	  used	  in	  the	  treatment	  for	  
HIV.	   A	   thorough	   medication	   history	   must	   therefore	   be	   part	   of	   the	   routine	   management	   of	   HIV	  
patients	   using	   ritonavir.	   Low	  morning	   cortisol	   and	   ACTH	   levels,	   low	   urinary	   cortisol	   excretion	   and	  
blunted	   response	   on	   the	   synthetic	   ACTH	   stimulation	   test	  will	   confirm	   this	   diagnosis.	  Management	  
options	  include	  replacing	  fluticasone	  and/or	  ritonavir.	  	  
	  
	  
	  Learning	  points	  
• The	   strong	   drug	   interaction	   between	   inhaled	   fluticasone	   and	   the	   potent	   CYP3A4	   inhibitor	  
ritonavir	  can	  lead	  to	  iatrogenic	  Cushing’s	  syndrome	  and	  secondary	  adrenal	  insufficiency.	  
• Lipodystrophy	  due	  to	  antiretrovirals	  can	  mimic	  the	  diagnosis	  of	  Cushing’s	  syndrome.	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